Lilly’s Van Naarden: Nothing is off the table for dealmaking

CNBC’s Angelica Peebles sits down with Lilly’s President of Oncology and Head of Business Development at the largest global cancer conference, ASCO. Van Naarden says that when it comes to choosing the right companies to go after, he’s driven by the most compelling science. Lilly is navigating how to spend it’s GLP-1 windfall and most recently inked four deals that expanded the portfolio into the infectious disease space.